Metformin Accord

Metformin, the active ingredient in Metformin Accord, is a Biguanide presented as a tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults, helping to lower elevated blood glucose levels by improving the body’s response to insulin and reducing hepatic glucose output.

GNH USA supplies Metformin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, and supporting reliable supply chains for chronic disease management.

Metformin is an oral antidiabetic agent used in the management of glucose metabolism disorders.

- Type 2 diabetes mellitus: improves glycemic control in adults. - Prediabetes: helps lower fasting glucose and may reduce progression to diabetes. - Polycystic ovary syndrome: assists in reducing insulin resistance and may improve menstrual regularity.

Metformin may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, often early in therapy. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration of taste perception. - Loss of appetite: reduced desire to eat. - Vitamin B12 deficiency: decreased absorption over long‑term use.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic acidosis. - Severe hypoglycemia: usually when combined with insulin or sulfonylureas. - Hepatic dysfunction: abnormal liver enzymes. - Pancreatitis: inflammation of the pancreas. - Skin rash or hypersensitivity: including Stevens‑Johnson syndrome. - Persistent gastrointestinal bleeding.

Metformin should be used with awareness of specific safety considerations.

- Renal function: assess creatinine clearance before initiation and periodically thereafter. - Hepatic disease: avoid in patients with significant liver impairment. - Cardiovascular status: monitor in patients with unstable heart failure. - Alcohol intake: limit consumption to reduce risk of lactic acidosis. - Pregnancy and lactation: evaluate risk‑benefit ratio with a healthcare professional. - Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture and direct sunlight.

Metformin may interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Iodinated contrast agents: can precipitate acute renal failure and increase lactic acidosis risk. - Cimetidine: may raise metformin plasma concentrations. - Nucleoside reverse transcriptase inhibitors (e.g., didanosine): increase risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycemia symptoms. - Diuretics (loop or thiazide): can affect renal clearance of metformin. - ACE inhibitors/ARBs: monitor renal function and electrolytes. - Corticosteroids: may raise blood glucose, requiring dose adjustment.